

The Linking of Cardiolipin Remodeling to Mitochondrial β -oxidation and Cardiolipin to T-cell function

Grant M. Hatch

Department of Pharmacology & Therapeutics
Manitoba Institute of Child Health (MICH)
Faculty of Medicine, University of Manitoba
Winnipeg, Manitoba, Canada



UNIVERSITY
OF MANITOBA







Synopsis

- Brief Introduction to cardiolipin
- Role of Stomatin-like protein 2 in altering cardiolipin and mitochondrial function in T-cells
- Role of α subunit of Human Trifunctional Protein in cardiolipin remodeling



Cardiolipin – a unique phospholipid!
glycerol

phosphodiester
bridge




phosphodiester
bridge

glycerol


glycerol



fatty acids




Cardiolipin



1. Major mitochondrial membrane phospholipid

- comprises 7-16% of the entire phospholipid mass of the cell depending upon the tissue
- 21% of phospholipid mass of the inner mitochondrial membrane
- synthesized on mitochondrial inner membrane


Cardiolipin



1. Major mitochondrial membrane phospholipid

2. Required for activation of enzymes of electron transport chain/respiratory supercomplex assembly

- both content and fatty acid composition are important
- e.g. delipidated cytochrome oxidase is reconstituted by addition of cardiolipin
- cardiolipin is the “glue” that holds the respiratory chain supercomplexes together




Cardiolipin

1. Major mitochondrial membrane phospholipid
2. Required for activation of enzymes of electron transport chain

3. Role in protein and lipid import into mitochondria

- CDP-DG, phosphatidylserine, malate dehydrogenase, ornithine carbamyltransferase precursor proteins

Cardiolipin




1. Major mitochondrial membrane phospholipid
2. Required for activation of enzymes of electron transport chain
3. Role in protein and lipid import into mitochondria


4. Regulator of apoptosis

- required for caspase-8 activation
- CL/MLCL binds to Bid/t-Bid, regulated by PLS3
- > cytochrome c release from mitochondria

Mammalian Cardiolipin *de novo* Biosynthesis: “The CDP-DG Pathway”




Human and Mammalian Cardiac Cardiolipin is Highly Enriched with 18:2 (Tetralinoleoyl-CL or L₄-CL)




Major Cardiolipin Species

<i>sn</i> -1- <i>sn</i> -2	<i>sn</i> -2- <i>sn</i> -1	%
18:2-18:2	18:2-18:2	80
18:2-18:1	18:2-18:2	} 12
18:1-18:2	18:2-18:2	



Adapted from: Schlame et al. 2005 Chem. Phys. Lipids 138, 38-49

Cardiolipin Remodeling Pathways



Adapted from: Hauff and Hatch (2006) Prog. Lipid Res. 45, 91-101.

Synopsis

- Brief Introduction to cardiolipin


Role of Stomatin-like protein 2 in altering cardiolipin and mitochondrial function in T-cells

Role of α subunit of Human Trifunctional Protein in cardiolipin remodeling


Stomatin-like protein 2 (SLP-2)

- stomatin – prohibitin – flotillin – HflC/K (SPFH) superfamily
- highly conserved family of proteins that mediate interactions with cell membranes
- upregulated in many cancers
- modulates MMP and ATP production

SLP-2 is Upregulated Upon Peripheral Blood Mononuclear Cell Activation



SLP-2 Localizes to the Immunological Synapse Upon Jurkat T-Cell Activation



SLP-2 polarizes to the immunological synapse during T cell activation
(*Christie et al 2012 PloS One*)




SLP-2 expression increases effector responses whereas down-regulation of SLP-2 correlates with loss of TCR signaling and activation
(*Kirchhof et al. 2008 J. Immunol.*)

SLP-2 is Localized Primarily to Mitochondria in Jurkat T-Cells





SLP-2-gfp

MitoTracker Red


Merge





Expression of SLP-2 in T-cells Increases Number of Metabolically Active Mitochondria





SLP-2 Expression in T-Cells Stimulates Cardiolipin and Mitochondrial Biogenesis




SLP-2 Binds to Cardiolipin







SLP-2 Interacts with Prohibitins




SLP-2 Expression in T-Cells Stimulates Mitochondrial Activity and Interleukin-2 Secretion in Response to T-Cell Stimulation






T-Cell Specific SLP-2 Knock Out Mice Exhibit Near Normal T-cell Number



T-Cells Deficient in SLP-2 Exhibit Reduced Mitochondrial Complex Protein/Activities, insoluble Prohibitin-1 and Cardiolipin



T-Cell Specific SLP-2 Knock Out Reduces *in vivo* Interleukin-2 Secretion in Response to T-Cell Stimulation and Delays Cardiac Allograft rejection



Summary I:

SLP-2 expression in T-cells stimulates cardiolipin and mitochondria biogenesis/activity and T-cell ability to respond to stimuli

Christie et al., Mol. Cell. Biol. 2011, 31:3845-3856.

SLP-2 KO in T-cells reduces cardiolipin in PHB complex fractions, mitochondrial metabolism and T-cell ability to respond to stimuli linking cardiolipin to T-cell function

Christie et al., J. Immunol. 2012 (in revision)

SLP-2 functions to recruit prohibitins to cardiolipin-enriched microdomains in which ETC complexes are optimally assembled





June 2012 Vol 32, Issue 11

Synopsis

- Brief Introduction to cardiolipin
- Role of Stomatin-like protein 2 in altering cardiolipin and mitochondrial function in T-cells
- **Role of α subunit of Human Trifunctional Protein in cardiolipin remodeling**

Expression of human MLCL AT-1 in Barth Syndrome lymphoblasts (patient Δ TAZ1) increases cardiolipin and mitochondrial Complex II + III activity



Human MLCL AT-1 is a shortened version (59 kDa) of the α subunit of Human Trifunctional Protein (74 kDa)

```

|----- TRANSIT PEPTIDE REGION -----|
NP_000173      1  MVACRAIGILSRFSAFRILRSRGYICRNFTGSSALLTRTHINYGVKGDVAVVRINSPNKVNLTLSKELHSEFSEVMNEIW
PreMeMLCL AT  -----
MLCL AT       -----

NP_000173      81  ASDQIRSAVLISSKPGCFIAGADINMLAACKTLQE-VTQLSQEAQRIVEKLEKSTKPIVAAINGSCLGGGLEVAISCQY
PreMeMLCL AT  -----
MLCL AT       -----

|----- TRANSIT PEPTIDE REGION -----|
NP_000173     159  RIATKDRKTVLGTPEVLLGALPGAGGTQRLPKMVGVPAAALDMMLTGRSIRADRAKMGMLVDQLVEPLGPGPKPPEERTIE
PreMeMLCL AT  1  -----MVGVPAAALDMMLTGRSIRADRAKMGMLVDQLVEPLGPGPKPPEERTIE
MLCL AT       1  -----PGLKPPPEERTIE

NP_000173     239  YLEEVAITFAKGLADKKISPKRDKGLVEKLTAYAMTIPFVRQQVYKRVKVEKVRKQTRGLYPAPLKIIDVVKTGIEQGS
PreMeMLCL AT  49  YLEEVAITFAKGLADKKISPKRDKGLVEKLTAYAMTIPFVRQQVYKRVKVEKVRKQTRGLYPAPLKIIDVVKTGIEQGS
MLCL AT       13  YLEEVAITFAKGLADKKISPKRDKGLVEKLTAYAMTIPFVRQQVYKRVKVEKVRKQTRGLYPAPLKIIDVVKTGIEQGS

NP_000173     318  AGYLCESQKFGELVMTKESKALMGLYHGQVLCCKNKFAGAPQKDVKHLAILGAGLMGAGIAQVSVDRGLKTIKDATLT
PreMeMLCL AT  128  AGYLCESQKFGELVMTKESKALMGLYHGQVLCCKNKFAGAPQKDVKHLAILGAGLMGAGIAQVSVDRGLKTIKDATLT
MLCL AT       92  AGYLCESQKFGELVMTKESKALMGLYHGQVLCCKNKFAGAPQKDVKHLAILGAGLMGAGIAQVSVDRGLKTIKDATLT

NP_000173     396  ALDRGQQQVFKGLNDKVKKKALTSFERDSIFSNLTGQLDYQGFEKADMVIEAVFEDLSLKHVRVLEVEAVIPDHCIFASN
PreMeMLCL AT  206  ALDRGQQQVFKGLNDKVKKKALTSFERDSIFSNLTGQLDYQGFEKADMVIEAVFEDLSLKHVRVLEVEAVIPDHCIFASN
MLCL AT       170  ALDRGQQQVFKGLNDKVKKKALTSFERDSIFSNLTGQLDYQGFEKADMVIEAVFEDLSLKHVRVLEVEAVIPDHCIFASN

NP_000173     476  TSALPISEIAAVSKRPEKVIKGMHYFSPVDRMQLLEIITTEKTSKDTASAVAVGLKQKQVIVVKDGGPGFYTTTRCLAPMM
PreMeMLCL AT  286  TSALPISEIAAVSKRPEKVIKGMHYFSPVDRMQLLEIITTEKTSKDTASAVAVGLKQKQVIVVKDGGPGFYTTTRCLAPMM
MLCL AT       250  TSALPISEIAAVSKRPEKVIKGMHYFSPVDRMQLLEIITTEKTSKDTASAVAVGLKQKQVIVVKDGGPGFYTTTRCLAPMM

NP_000173     556  SEVIRILQEGVDPKKLDS-LTTSFGFPVGAATLVDEVGVDAKHVAEDLGKVFGERFSGGNPELLTQMVSKGFLGRKSGK
PreMeMLCL AT  366  SEVIRILQEGVDPKKLDS-LTTSFGFPVGAATLVDEVGVDAKHVAEDLGKVFGERFSGGNPELLTQMVSKGFLGRKSGK
MLCL AT       330  SEVIRILQEGVDPKKLDS-LTTSFGFPVGAATLVDEVGVDAKHVAEDLGKVFGERFSGGNPELLTQMVSKGFLGRKSGK

NP_000173     635  GFYIYQ---EGVKKRDLNSDMDSILASLKLPPKSEVSSDEDIQFRLVTRFVNEAVMCLQEGILATPAEGDIGAVFGLGFP
PreMeMLCL AT  445  GFYIYQ---EGVKKRDLNSDMDSILASLKLPPKSEVSSDEDIQFRLVTRFVNEAVMCLQEGILATPAEGDIGAVFGLGFP
MLCL AT       409  GFYIYQ---EGVKKRDLNSDMDSILASLKLPPKSEVSSDEDIQFRLVTRFVNEAVMCLQEGILATPAEGDIGAVFGLGFP

NP_000173     712  PCLGGPFRFVDLYGAQKIVDRLKKYEAAYGKQFTPCQLLADHANSFNKKFYQ----- 763
PreMeMLCL AT  522  PCLGGPFRFVDLYGAQKIVDRLKKYEAAYGKQFTPCQLLADHANSFNKKFYQ----- 573
MLCL AT       486  PCLGGPFRFVDLYGAQKIVDRLKKYEAAYGKQFTPCQLLADHANSFNKKFYQ----- 537

```


Human MLCL AT-1 is a shortened version (59 kDa) of the α subunit of Human Trifunctional Protein (74 kDa)

Trifunctional protein

- multifunctional, membrane-bound beta-oxidation enzyme protein catalyzing three enzyme activities:
 - long-chain enoyl-Coenzyme A hydratase
 - long-chain 3-hydroxyacyl-Coenzyme A-dehydrogenase
 - long-chain 3-oxoacyl-Coenzyme A thiolase
- heterocomplex of two subunits, 4 alpha and 4 beta







```

| -          TRANSIT PEPTIDE REGION          - |
NP_000173  1  MVACRAIGILSRFSAFRILRSRGYICRNFTGSSALLTRTHINYGVKGDVAVVRINSPNSKVNLTLSKELHSEFSEVMNEIW
PreMtMLCL AT  -----
MLCL AT      -----

NP_000173  81  ASDQIRSAVLISSKPGCFIAGADINMLAACKTLQE-VTQLSQEAQRIVEKLEKSTKPIVAAINGSCLEGGGLEVAISCQY
PreMtMLCL AT  -----
MLCL AT      -----

| -          TRANSIT PEPTIDE REGION          - |
NP_000173  159 RIATKDRKTVLGTPEVLLGALPGAGGTQRLPKMVGVPAAALDMMMLTGRSIRADRANKMGLVDQLVEPLGPGPKPPEERTIE
PreMtMLCL AT  1  -----MVGVPAAALDMMMLTGRSIRADRANKMGLVDQLVEPLGPGPKPPEERTIE
MLCL AT      1  -----PGLKPPEERTIE
```

Human recombinant α subunit of Trifunctional Protein exhibits MLCL AT *in vitro* activity and stimulates [1- 14 C]fatty acid incorporation into cardiolipin in Hela cells







MLCL AT-1 is likely a splice variant of the α subunit of Trifunctional Protein

```


      |----- TRANSIT PEPTIDE REGION -----|
NP_000173      1  MVACRAIGILSRFSAPRILRSRGYICRNFTGSSALLTRTHINYGKGDVAVVRINSFNSKVNWLSKELHSEFSEVMNEIW
Pre-McMLCL AT  -----
MLCL AT       -----

NP_000173     81  ASDQIRSAVLISSKPGCFIAGADINMLAACKTLQE-VTQLSQEAQRIVEKLEKSTKPIVAAINGSCLGGGLEVAISCQY
Pre-McMLCL AT  -----
MLCL AT       -----



      |----- TRANSIT PEPTIDE REGION -----|
NP_000173    159  RIATKDRKTVLGTPEVLLGALPGAGGTQRLPKMVGVPALDMLTGRSIRADRAKMGGLVDQLVEPLGPKPPEERTIE
Pre-McMLCL AT  1  -----MVGVPALDMLTGRSIRADRAKMGGLVDQLVEPLGPKPPEERTIE
MLCL AT       1  -----PGLKPFPEERTIE
  
```




Expression of MLCL AT-1 or α subunit of Trifunctional Protein in Normal or BTHS Lymphoblasts increases L₄-cardiolipin



Lysophospholipid	Enzyme activity (pmol/min/mg protein)
Monolysocardiolipin	56.3 ± 1.3
Lysophosphatidic acid	ND
Lysophosphatidylglycerol	ND
Lysophosphatidylcholine	ND
Lysophosphatidylethanolamine	ND



MLCL AT enzyme activity is not increased by knock down of TAZ in normal human lymphoblasts but MLCL AT-1 expression restores [1-¹⁴C]linoleate into cardiolipin after TAZ knock down



Summary II:

α TFP exhibits MLCL AT activity and expression of α TFP stimulates cardiolipin remodeling with linoleate and increases L₄-cardiolipin levels in normal and BTHS lymphoblasts linking an enzyme of β -oxidation to cardiolipin remodeling

Taylor et al. Biochem. J. 2012 (submitted)

MLCL AT-1 activity is not increased by *TAZ* knock down indicating that *TAZ* and MLCL AT-1 may not complement each other in cardiolipin remodeling but MLCL AT-1 expression may compensate for loss of *TAZ*

Current Studies:

- 1. Will expression of MLCL AT-1 or α TFP in Taz knock down mice attenuate development of the cardiac defects?**
- 2. Role of SLP-2 in mitochondrial dysfunction in BTHS**

Acknowledgements

Hatch lab:

William Taylor, Fred Xu, Edgard Mejia, Laura Cole

Darah Christie, Quim Madrenas – Robarts Research Institute, McGill University
Genevieve Sparagna, Robert Murphy – University of Colorado at Boulder
Zaza Khuchua – Childrens' Hospital Medical Center, Cincinnati

Funding:

